©2007 Baishideng Publishing Group Co., Limited. All rights reserved.
Cell culture systems for the hepatitis C virus
Gilles Duverlie, Virology Laboratory, Amiens University Hospital, Amiens, F-80054 Amiens cedex 1, France and Hepatitis C Unit, Institut de Biologie de Lille, 1 rue du Pr Calmette, BP 447, F-59021 Lille cedex, France
Czeslaw Wychowski, Hepatitis C Unit, Institut de Biologie de Lille, 1 rue du Pr Calmette, BP 447, F-59021 Lille cedex, France
Author contributions: All authors contributed equally to the work.
Correspondence to: Gilles Duverlie, Laboratoire de Virologie, Hôpital Sud, CHU d’Amiens, 80054 Amiens cedex 1,France. email@example.com
Telephone: +33-322-827917 Fax: +33-322-827928
Received: January 29, 2007
Revised: February 2, 2007
Accepted: March 12, 2007
Published online: May 7, 2007
Since the discovery of the hepatitis C virus (HCV) via molecular cloning in 1989, its propagation in cell culture has been a major goal for virologists worldwide. All human hepatitis viruses are very difficult to grow in cell culture, and indeed no such system is currently available for the hepatitis B virus (HBV). This problem is also linked to the nature of the host cell, since highly differentiated human hepatocytes are very difficult to maintain in cell culture. However, it has been demonstrated that blood or serum from chronically infected HCV patients is infectious in vivo and does contain infectious virions suitable for the in vitro infection of cultured hepatocytes.
IN VITRO INFECTION BY HCV STRAINS FROM PATIENTS
In 1992, Shimizu et al were the first to report successful HCV infection of the human T-lymphocyte MOLT-4Ma and HPB-Ma lines which had been pre-infected with murine retroviruses. In 1995, Kato et al reported similar results with the MT-2 cell line pre-infected with HTLV-I. Use of clone 10-2 of the HPB-Ma cell line enabled a one-year follow-up of the infection, with neutralization by antibodies, inhibition of replication by interferon, visualisation of 50 nm particles by immuno-electronmicroscopy and analysis of the virion density. However, in these and other cell lines (Daudi, PBMC, etc.), viral replication could be only intermittently detected by RT-PCR. The human hepatoma cell lines Huh-7 and Hep-G2 could support HCV replication, as did other hepatocytic cell lines immortalized by the SV-40 T antigen. Ito et al have cultured primary hepatocytes from chronically infected HCV patients and have obtained relatively high viral titers in both the cells and the supernatant medium. Primary chimpanzee and human hepatocytes are permissive to HCV for the very limited time during which these cells are usable[7-9]. These data indicate that HCV replication (at least) was possible in hepatocyte and lymphocyte cell lines. However, these systems were not reliable and could not be used as models for studying the viral cycle in detail or for screening antiviral drugs. These goals should be achieved by using viral and cellular clones under stable infection conditions. Reverse genetics studies are also very helpful, and it is noteworthy that viral genomes are generally small enough to be engineered by today's oligonucleotide ligation techniques, marking the passage from macromolecular chemistry to "life".
FULL-LENGTH, INFECTIOUS HCV CDNA
HCV is a member of the Flaviviridae and harbours an envelope with two glycoproteins and a nucleocapsid containing a positive single-strand RNA genome of about 9600 nucleotides. The positive viral RNA (vRNA) has the same polarity as mRNA and can be directly translated in order to express the full set of viral proteins and initiate the viral life cycle. The vRNAs are generated by transcription of cloned, complementary DNA (cDNA) obtained by reverse transcription. The first cloned HCV genomes were incomplete, and a novel sequence at the 3' terminus of the hepatitis C virus was only discovered in 1995 by use of oligonucleotide ligation or synthesis at the 3'end of the HCV genome[12,13].
The first "infectious" cDNA from HCV genotype 1 was successfully obtained by two different groups in 1997[14,15]. The HCV genome (called "H77") was cloned from the serum of an infected patient with a high viral titer. The sequences of many different clones were aligned, a master consensus sequence was established and a full-length HCV consensus sequence was then generated. It was supposed that the viral quasispecies contained a majority of functional genomes with a minority of defective ones, as observed for other viruses. Thus, the establishment of a master consensus sequence is one approach to detecting deleterious mutations in defective virions or mutations introduced by amplification and/or molecular cloning. The identification of an infectious cDNA was successfully achieved, since the transcribed RNAs were able to infect the chimpanzee when inoculated intrahepatically. Other full-length genomic HCV cDNAs have since been established but none of these clones have been adapted to cell culture, as only very low levels of replication were reported[15,17,18].
HCV SUBGENOMIC REPLICONS
New strategies based on the subgenomic selectable HCV replicon were developed in order to enable the selection of cell clones containing autonomously replicating HCV RNAs. In 1999, Lohmann et al established the first HCV genotype 1b replicon in the Huh-7 hepatoma cell line. Replicons are subgenomic constructs expressing the viral replicase complex and capable of autonomous viral replication. As with other positive RNA viral genomes, the authors constructed bicistronic vectors-allowing the exact transcription of the HCV 5' and 3' non-translated regions (NTRs)-and then used (1) the HCV internal ribosomal entry site (IRES) to ensure translation of the neomycin phosphotransferase gene (neo) and (2) the EMCV IRES to ensure translation of the HCV replicase complex (at least from NS3 to NS5B). Thus, neomycin-resistant cell clones containing replicating HCV RNAs were then selected. This successful approach enabled the selection of highly permissive cell clones (such as Huh-7.5 and Huh-7-Lunet[20,21]) and adaptive viral mutations (involving principally the NS3, NS4B and NS5A regions). Several of these mutations alter the phosphorylation state of NS5A, the hyperphosphorylated form of which appears to be deleterious for efficient HCV replication[23,24]. These replicons have been very valuable tools for studying HCV replication and for testing antiviral drugs against HCV's major target enzymes, i.e. NS3 helicase, NS3/4A protease and NS5B polymerase. Full-length genomic replicons using the consensus approach (such as the wild type Con-1) failed to produce infectious particles when tested, since very low numbers of viral particles were obtained. Indeed, the different markers enabled the selection of replicative genomic sequences but were not appropriate for selecting for viral particle secretion. Selective pressure acts on the replicase complex (involving most of HCV's non-structural proteins) but not on structural proteins. Furthermore, at least some adaptive mutations seemed to optimize viral replication and impair viral particle production. Interestingly, some replicons were reported as being free of adaptive mutations and were able to replicate at a very high rate.
VIRAL PRODUCTION IN CELL CULTURE
Eventually, one of the above-mentioned full-length replicons was found to release viral particles. The replicon was a HCV genotype 2a clone called JFH-1, constructed by Takaji Wakita's group and isolated from a Japanese patient with fulminant hepatitis. It is the first authentic HCV clone considered by the scientific community as capable of growing in cell culture. Transfection of the full-length JFH-1 genome into Huh-7 cells leads to the production of HCV particles that are infectious for naive cells and for chimpanzees. Given that full-length genomic RNA derived from other clones of the same genotype or different HCV genotypes was again not infectious in a cell culture system, chimeric viruses were constructed successfully. Hence, the sequences coding for the HCV JFH-1 structural proteins were replaced by the corresponding sequences from different HCV genotypes[30,31]. The HCV chimera's junction was situated in the NS2 protein, just after the first transmembrane domain in a junction region which has also been identified in the rare, naturally-occurring recombinant forms of HCV (generally found in isolates from intravenous drug users). However, the viral titer obtained for most constructs was low, with the exception of the FL-J6-JFH1 chimeric 2a-2a recombinant virus. This homologous, chimeric form was shown to be infectious in the chimpanzee, and the virus recovered from the infected animal was infectious in cell culture. Comparison of the viral titers obtained by Dr. Wakita's group with those observed by other groups indicates that cell culture conditions may influence viral production. Continuous passages of infected cells or successive infections of naive cells with the supernatant of infected cells leads to an increase in viral production. This finding suggests that certain mutations are probably selected during the infection. Determinants present in the structural proteins may be important for viral release and infection in cell culture. Thus, a detailed study of the key features enabling operation of the complete HCV cell cycle should enable researchers to cultivate other isolates. Very recently, a genotype 1a (H77) virus production system producing low viral titers has been described.
Another improvement concerns the cell line used for HCV culturing. Certain clones of the Huh-7 cell line were found to far better than others for growing HCV. "HCV-cured clones" produced by antiviral agents and Huh-7 subclones (such as Huh-7.5 and now Huh-7.5.1 or Huh-7-Lunet) support more efficient viral replication and production. Detailed studies have shown that some important features (such as high levels of CD81 receptor expression or perhaps SR-B1 or claudin-1 very recently identified by the Rice's group) could increase viral pro-duction and spreading. Indeed, as shown in Figure 1, HepG2 cells which are not usually susceptible to HCV can be infected by the JFH1 virus when they express CD81. Furthermore, defects in innate immunity (such as deficiencies in interferon induction or production) could increase the cell line's permissivity[35,36]. Identification of new cell lines of hepatic (or perhaps lymphocyte) origin could improve our understanding of certain phy-siopathological aspects of hepatitis C. Equally, HCV pro-duction in cell lines from other species (such as murine cell lines) could help to establish a small animal model of HCV infection.
Figure 1 Infection of different hepatoma cell lines by JFH1 virus.
HepG2 not expressing the CD81 receptor, HepG2 expressing the CD81 receptor and Huh-7 cell- lines were used for the infection. Cells seeded at between 3 and 5. 105 cells per well in 24-well plates were incubated for 2 h at 37°C with 200 mL of culture medium containing infectious JFH1 virus (obtained after successive re-infection of naive Huh-7 cells). Cells were processed and immunostained for the detection of capsid, as previously described (Rouillé et al., 2006, J Virol, 80). The Figure shows the detection of HCV capsid protein in HepG2-CD81 and Huh-7 cells but not in HepG2 cells. Re-infection of naive HepG2-CD81 and Huh-7 cells is effective with the resulting supernatant from each infection.
The new cell culture system represents a major breakthrough in the HCV field and should enable a broad range of fundamental and applied studies to be achieved, including the production of classic HCV vaccines for efficacy testing. Detailed cellular, molecular and reverse genetics studies are also needed to complete our knowledge of all aspects of HCV's biology.
The identity of the infectious form of HCV in "real life" remains open to debate because HCV in sera is strongly associated with lipoproteins; certain features (such as the infectious form's density) appear to differ from those seen in the HCV particles produced in cell culture systems (HCVcc). New information concerning the receptor(s) involved and other important determinants of permissivity will be valuable for improving the culture system. These new insights could enable researchers to grow clinical HCV isolates and study their particular features.
S- Editor Wang J E- Editor Ma WH